Cancers display widespread RNA dysregulation, including alternative splicing of transcripts. These aberrant transcripts are often translated into cancer-specific proteins and have been shown to affect cancer initiation, progression, metastasis, and drug resistance. While it has been recently reported that cancer-specific isoforms can be used as novel prognostic biomarkers and serve as an untapped source of drug targets for immuno-oncology, the vast majority of cancer specific isoforms remain unknown. With at least 95% of genes undergoing alternative splicing and producing multiple isoforms, much remains to be discovered.
Join us for this webinar to learn:
Register for webinar
The Jackson Laboratory